Patents by Inventor Evelina Angov

Evelina Angov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant merozoite protein-1vaccine
    Patent number: 7256281
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 14, 2007
    Assignees: United States of America as represented by the Secretary of the Army
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
  • Isolation and purification of P. falciparum merozoite protien-142 vaccine
    Publication number: 20060148010
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: January 24, 2005
    Publication date: July 6, 2006
    Inventors: Jeffrey Lyon, Evelina Angov
  • Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
    Publication number: 20060088547
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Application
    Filed: November 12, 2003
    Publication date: April 27, 2006
    Inventors: David Lanar, Collette Hillier, Jeffrey Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Isolation and purification of P. falciparum merozoite protein-142 vaccine
    Patent number: 6855322
    Abstract: This application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: February 15, 2005
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov
  • Protein expression by codon harmonization and translational attenuation
    Publication number: 20040209323
    Abstract: The present invention is based in the fields of molecular genetics and recombinant protein expression. The invention features compositions and methods for increasing the expression levels of proteins expressed in non-natural hosts. Increased expression levels are achieved by expression of a translationally-harmonized nucleic acid that is created by substituting certain codons having low or intermediate usage frequency in the natural host with synonymous codons that have low or intermediate usage frequency in the non-natural host.
    Type: Application
    Filed: October 1, 2003
    Publication date: October 21, 2004
    Applicant: Veritas
    Inventors: Randall L. Kincaid, Evelina Angov, Jeffrey A. Lyon
  • Recombinant P. falciparum merozoite protein-142 vaccine
    Publication number: 20040005332
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 8, 2004
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
  • Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
    Publication number: 20040005600
    Abstract: The present invention provides a method for modifying a wild type nucleic acid sequence encoding a polypeptide to enhance expression and accumulation of the polypeptide in the host cell by harmonizing synonymous codon usage frequency between the foreign DNA and the host cell DNA. This can be done by substituting codons in the foreign coding sequence with codons of similar usage frequency from the host DNA/RNA which code for the same amino acid. The present invention also provides novel synthetic nucleic acid sequences prepared by the method of the invention.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 8, 2004
    Inventors: Evelina Angov, Jeffrey A. Lyon, Randall L. Kincaid
  • Recombinant P. falciparum merozoite protein-142 vaccine
    Publication number: 20030161839
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: January 25, 2002
    Publication date: August 28, 2003
    Inventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
  • Isolation and purification of P. falciparum merozoite protein-142 vaccine
    Publication number: 20030161838
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: January 25, 2002
    Publication date: August 28, 2003
    Inventors: Jeffrey A. Lyon, Evelina Angov
  • Cloning of the recA gene from thermus aquaticus YT-1
    Patent number: 5510473
    Abstract: The present invention includes the isolation of an oligonucleotide encoding Thermus aquaticus recA protein, and to the purified protein. The invention also includes methods of use of the protein, particularly, methods for hybridizing a primer to a complementary template with increased binding affinity at a temperature above 45.degree. C.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: April 23, 1996
    Assignee: The United States of American as represented by the Secretary of Health and Human Services
    Inventors: Rafael D. Camerini-Otero, Evelina Angov